A pharmacological modification of pain and epithelial healing in contemporary transepithelial all-surface laser ablation (ASLA)

Ioannis M Aslanides, Vasilis D Selimis, Nikolaos V Bessis, Panagiotis N Georgoudis Emmetropia Mediterranean Eye Institute, Heraklion, Crete, Greece Purpose: We report our experience with the use of the matrix regenerating agent (RGTA) Cacicol® after reverse transepithelial all-surface las...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aslanides IM, Selimis VD, Bessis NV, Georgoudis PN
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/59531965299c4123862eedbb41bc2c12
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:59531965299c4123862eedbb41bc2c12
record_format	dspace
spelling	oai:doaj.org-article:59531965299c4123862eedbb41bc2c122021-12-02T09:07:09ZA pharmacological modification of pain and epithelial healing in contemporary transepithelial all-surface laser ablation (ASLA)1177-5483https://doaj.org/article/59531965299c4123862eedbb41bc2c122015-04-01T00:00:00Zhttp://www.dovepress.com/a-pharmacological-modification-of-pain-and-epithelial-healing-in-conte-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483 Ioannis M Aslanides, Vasilis D Selimis, Nikolaos V Bessis, Panagiotis N Georgoudis Emmetropia Mediterranean Eye Institute, Heraklion, Crete, Greece Purpose: We report our experience with the use of the matrix regenerating agent (RGTA) Cacicol® after reverse transepithelial all-surface laser ablation (ASLA)-SCHWIND to assess the safety, efficacy, pain, and epithelial healing.Methods: Forty eyes of 20 myopic patients were prospectively recruited to a randomized fellow eye study. Patients underwent transepithelial ASLA in both eyes, with one of the eyes randomly assigned to the use of the RGTA Cacicol. Postoperative pain and vision were subjectively assessed with the use of a questionnaire on the operative day, at 24 hours, 48 hours and 72 hours. Epithelial defect area size was measured at 24 hours, 48 hours, and 72 hours. Uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA) were assessed at 1 month.Results: Mean UDVA at 1 month was LogMAR 0.028. The epithelial defect area was 10.91 mm2 and 13.28 mm2 at 24 hours and 1.39 mm2 and 1.24 mm2 at 48 hours for treated and nontreated eyes, respectively. Overall, 50% and 65% of treated and nontreated eyes healed by 48 hours. There was no statistically significant difference in the subjective vision between the groups, although vision of patients in the RGTA group was reported to be better. Pain scores were better at 24 hours and 48 hours in the RGTA group but with no statistically significant difference.Conclusion: The use of RGTA Cacicol shows faster epithelial recovery after transepithelial ASLA for myopia. Subjectively reported scores of pain and subjective vision were better in the RGTA group, although the difference was not statistically significant. There seems to be a consensual acceleration of epithelial healing even in eyes that did not receive treatment. There were no adverse events and no incidents of inflammation, delayed healing, or haze. Keywords: matrix regenerating agent, photorefractive keratectomy, PRK, transepithelialAslanides IMSelimis VDBessis NVGeorgoudis PNDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2015, Iss default, Pp 685-690 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Aslanides IM Selimis VD Bessis NV Georgoudis PN A pharmacological modification of pain and epithelial healing in contemporary transepithelial all-surface laser ablation (ASLA)
description	Ioannis M Aslanides, Vasilis D Selimis, Nikolaos V Bessis, Panagiotis N Georgoudis Emmetropia Mediterranean Eye Institute, Heraklion, Crete, Greece Purpose: We report our experience with the use of the matrix regenerating agent (RGTA) Cacicol® after reverse transepithelial all-surface laser ablation (ASLA)-SCHWIND to assess the safety, efficacy, pain, and epithelial healing.Methods: Forty eyes of 20 myopic patients were prospectively recruited to a randomized fellow eye study. Patients underwent transepithelial ASLA in both eyes, with one of the eyes randomly assigned to the use of the RGTA Cacicol. Postoperative pain and vision were subjectively assessed with the use of a questionnaire on the operative day, at 24 hours, 48 hours and 72 hours. Epithelial defect area size was measured at 24 hours, 48 hours, and 72 hours. Uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA) were assessed at 1 month.Results: Mean UDVA at 1 month was LogMAR 0.028. The epithelial defect area was 10.91 mm2 and 13.28 mm2 at 24 hours and 1.39 mm2 and 1.24 mm2 at 48 hours for treated and nontreated eyes, respectively. Overall, 50% and 65% of treated and nontreated eyes healed by 48 hours. There was no statistically significant difference in the subjective vision between the groups, although vision of patients in the RGTA group was reported to be better. Pain scores were better at 24 hours and 48 hours in the RGTA group but with no statistically significant difference.Conclusion: The use of RGTA Cacicol shows faster epithelial recovery after transepithelial ASLA for myopia. Subjectively reported scores of pain and subjective vision were better in the RGTA group, although the difference was not statistically significant. There seems to be a consensual acceleration of epithelial healing even in eyes that did not receive treatment. There were no adverse events and no incidents of inflammation, delayed healing, or haze. Keywords: matrix regenerating agent, photorefractive keratectomy, PRK, transepithelial
format	article
author	Aslanides IM Selimis VD Bessis NV Georgoudis PN
author_facet	Aslanides IM Selimis VD Bessis NV Georgoudis PN
author_sort	Aslanides IM
title	A pharmacological modification of pain and epithelial healing in contemporary transepithelial all-surface laser ablation (ASLA)
title_short	A pharmacological modification of pain and epithelial healing in contemporary transepithelial all-surface laser ablation (ASLA)
title_full	A pharmacological modification of pain and epithelial healing in contemporary transepithelial all-surface laser ablation (ASLA)
title_fullStr	A pharmacological modification of pain and epithelial healing in contemporary transepithelial all-surface laser ablation (ASLA)
title_full_unstemmed	A pharmacological modification of pain and epithelial healing in contemporary transepithelial all-surface laser ablation (ASLA)
title_sort	pharmacological modification of pain and epithelial healing in contemporary transepithelial all-surface laser ablation (asla)
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/59531965299c4123862eedbb41bc2c12
work_keys_str_mv	AT aslanidesim apharmacologicalmodificationofpainandepithelialhealingincontemporarytransepithelialallsurfacelaserablationasla AT selimisvd apharmacologicalmodificationofpainandepithelialhealingincontemporarytransepithelialallsurfacelaserablationasla AT bessisnv apharmacologicalmodificationofpainandepithelialhealingincontemporarytransepithelialallsurfacelaserablationasla AT georgoudispn apharmacologicalmodificationofpainandepithelialhealingincontemporarytransepithelialallsurfacelaserablationasla AT aslanidesim pharmacologicalmodificationofpainandepithelialhealingincontemporarytransepithelialallsurfacelaserablationasla AT selimisvd pharmacologicalmodificationofpainandepithelialhealingincontemporarytransepithelialallsurfacelaserablationasla AT bessisnv pharmacologicalmodificationofpainandepithelialhealingincontemporarytransepithelialallsurfacelaserablationasla AT georgoudispn pharmacologicalmodificationofpainandepithelialhealingincontemporarytransepithelialallsurfacelaserablationasla
_version_	1718398245204393984

A pharmacological modification of pain and epithelial healing in contemporary transepithelial all-surface laser ablation (ASLA)

Ejemplares similares